EyePoint Pharmaceuticals, Inc. Common Stock (EYPT)
EyePoint Pharmaceuticals, Inc. (EYPT) is a pharmaceutical company focused on developing and commercializing innovative therapies for eye diseases. The company specializes in treatments for retinal diseases, uveitis, and other ocular conditions, leveraging its expertise in drug delivery and molecular innovation to address unmet medical needs in ophthalmology.
Company News
EyePoint Pharmaceuticals plans to raise approximately $150 million through a public offering of 11 million common stock shares and pre-funded warrants, with proceeds intended to advance clinical development of DURAVYU for retinal diseases.
EyePoint Pharmaceuticals announced a proposed public offering of $100 million in common stock to advance the clinical development of its lead product candidate DURAVYU for wet age-related macular degeneration and diabetic macular edema, as well as support its earlier stage pipeline.
Intra-Cellular (ITCI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
EyePoint's stock is on track for its biggest ever one-day percentage gain in heavy volume.
The company reported positive trial data for its lead therapy to treat two different eye conditions.